Literature DB >> 22548619

Treatments for diabetic neuropathy.

Vera Bril1.   

Abstract

Diabetic neuropathy comprises disorders of peripheral nerve in diabetes patients after exclusion of other disorders and can be focal or diffuse. The focal diabetic neuropathies tend to resolve spontaneously and are treated by reassurance, physiotherapy and analgesia for painful symptoms. Diabetic sensorimotor polyneuropathy (DSP) is the most frequent form of diabetic neuropathy and effective disease-modifying treatment is not available beyond the interventions of optimal glycemic control, and possibly lifestyle and risk factor modification. In contrast, a recent evidence-based guideline shows that effective treatments for painful DSP include: pregabalin, amitriptyline, duloxetine, venlafaxine, gabapentin, opioids, nitrate sprays, capsaicin, and transcutaneous electrical nerve stimulation. The choice of treatment is guided by the clinical status of the individual patient.
© 2012 Peripheral Nerve Society.

Entities:  

Mesh:

Year:  2012        PMID: 22548619     DOI: 10.1111/j.1529-8027.2012.00391.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  17 in total

Review 1.  Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?

Authors:  Victoria A Serhiyenko; Alexandr A Serhiyenko
Journal:  World J Diabetes       Date:  2015-03-15

Review 2.  Treatment of painful diabetic neuropathy.

Authors:  Saad Javed; Ioannis N Petropoulos; Uazman Alam; Rayaz A Malik
Journal:  Ther Adv Chronic Dis       Date:  2015-01       Impact factor: 5.091

3.  Synthesis of substituted 2H-benzo[e]indazole-9-carboxylate as a potent antihyperglycemic agent that may act through IRS-1, Akt and GSK-3β pathways.

Authors:  Gaurav Taneja; Chandra Prakash Gupta; Shachi Mishra; Rohit Srivastava; Neha Rahuja; Arun Kumar Rawat; Jyotsana Pandey; Anand P Gupta; Natasha Jaiswal; Jiaur R Gayen; Akhilesh K Tamrakar; Arvind Kumar Srivastava; Atul Goel
Journal:  Medchemcomm       Date:  2016-11-15       Impact factor: 3.597

Review 4.  Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era?

Authors:  Mingfang Sun; Min Zhang; Jing Shen; Juping Yan; Bo Zhou
Journal:  Int J Endocrinol       Date:  2015-04-27       Impact factor: 3.257

5.  Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy.

Authors:  Su-Yeon Park; Young-A Kim; Yoon-Ho Hong; Min-Kyong Moon; Bo-Kyeong Koo; Tae Wan Kim
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 6.  Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy.

Authors:  Md Tanvir Kabir; Nuzhat Tabassum; Md Sahab Uddin; Faissal Aziz; Tapan Behl; Bijo Mathew; Md Habibur Rahman; Raushanara Akter; Abdur Rauf; Lotfi Aleya
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-13       Impact factor: 2.629

7.  Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literature.

Authors:  Lampros Samartzis; Paraskevi Savvari; Sofoklis Kontogiannis; Stavros Dimopoulos
Journal:  Case Rep Psychiatry       Date:  2013-03-04

Review 8.  Diabetic neuropathy and oxidative stress: therapeutic perspectives.

Authors:  Asieh Hosseini; Mohammad Abdollahi
Journal:  Oxid Med Cell Longev       Date:  2013-04-24       Impact factor: 6.543

9.  The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo.

Authors:  Natalie C G Kwai; William Nigole; Ann M Poynten; Christopher Brown; Arun V Krishnan
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

10.  Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.

Authors:  Evan J H Lewis; Bruce A Perkins; Leif E Lovblom; Richard P Bazinet; Thomas M S Wolever; Vera Bril
Journal:  Neurology       Date:  2017-05-17       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.